What's better than momentum? Mo' momentum. Let's take a closer look at five of this past week's biggest scorchers.
|
Company |
Jan. 18 |
Weekly Gain |
My Watchlist |
|---|---|---|---|
|
Aurizon Mines (NYSEMKT: AZK) |
$4.67 |
35% |
|
|
Pacific Biosciences (PACB 0.65%) |
$3.00 |
20% |
|
|
Research In Motion (BB 1.82%) |
$13.56 |
13% |
|
|
Genworth Financial (GNW 0.33%) |
$9.15 |
13% |
|
|
Opko Health (OPK) |
$6.05 |
12% |
Source: Barron's.
Aurizon struck gold after receiving an unsolicited buyout offer. The gold producer, with projects in the Abitibi region of northwestern Quebec, announced on Friday that it formed a committee to explore the $792.6 million offer.
Pacific Biosciences of California continues to be one of the hottest stocks, up 76% so far this year and nearly tripling since bottoming out in November. There was no material news out on the DNA sequencing specialist this week, though momentum continues to linger since popping earlier this month, after a group including the FDA announced a new study based on Pacific Biosciences' technology.
Research In Motion continues to rally ahead of its Jan. 30 event for the big reveal of BlackBerry 10. There's a lot riding on the update to RIM's mobile operating system. As for news this past week, credit card issuing giant Visa approved RIM's mobile-payments solution.
Genworth Financial moved higher on a week where the news was largely mixed for financial companies. The wealth-management and financial-solutions provider moved on plans to separate its mortgage insurance business.
Opko Health hit a fresh 52-week high after its CEO continued his impressive string of share purchases. CEO Phillip Frost has now bought nearly $1.5 million worth of his company's stock this month. Opko also expanded its relationship with pharmaceuticals giant Bristol-Myers Squibb.
